問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
Principal Investigator
葉士芃
下載
2015-04-01 - 2023-12-31
Condition/Disease
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Test Drug
Pembrolizumab (MK-3475)
Participate Sites6Sites
Terminated5Sites
Division of Hematology & Oncology
2011-04-01 - 2018-07-31
Participate Sites4Sites
Terminated4Sites
2020-12-25 - 2025-07-31
diffuse large B-cell lymphoma (DLBCL)
Brentuximab Vedotin, Lenalidomide,Rituximab
Participate Sites7Sites
Recruiting7Sites
2019-11-30 - 2022-05-19
Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis
Momelotinib Tablets；Danazol Capsules
Not yet recruiting3Sites
Recruiting1Sites
2014-07-01 - 2023-10-25
Relapsed or Refractory Multiple Myeloma
Daratumumab
2015-03-01 - 2019-04-30
with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates
SGI-110 for subcutaneous injection
2012-06-01 - 2018-05-31
Terminated6Sites
2013-02-01 - 2021-12-31
2021-03-17 - 2025-06-15
Participate Sites8Sites
Recruiting8Sites
2021-07-30 - 2025-12-31
Recruiting4Sites
全部
